| Luisito Dingcong, | |
|
1033 Turnpike Ave, Clearfield Hospital, Clearfield, PA 16830-3061 | |
| (814) 768-2137 | |
| (814) 765-2084 |
| Full Name | Luisito Dingcong |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1033 Turnpike Ave, Clearfield, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841282738 | NPI | - | NPPES |
| 0014738630006 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD052607L (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Luisito Dingcong, Po Box 904, St Marys, PA 15857-0904 Ph: (814) 781-3624 | Luisito Dingcong, 1033 Turnpike Ave, Clearfield Hospital, Clearfield, PA 16830-3061 Ph: (814) 768-2137 |
News Archive
Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.
SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.
As diagnostic imaging and radiation treatment technologies both become more capable and precise, physicians using them face an increasingly difficult task: how to transfer information from the diagnostic systems to the treatment planning systems.
In 2002 ACEA Biosciences pioneered real-time cellular impedance as a tool for dynamically tracking cell number, cell size, cell-substrate attachment strength, and cell invasion/migration.
› Verified 8 days ago
Satish Amirneni, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 809 Turnpike Ave, C/o Bright Horizons(clearfield Hospital), Clearfield, PA 16830 Phone: 814-768-2184 |